Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Ilenia Varasi"'
Autor:
Camilla Biba, Lia Fiaschi, Ilenia Varasi, Chiara Paletti, Niccolò Bartolini, Maurizio Zazzi, Ilaria Vicenti, Francesco Saladini
Publikováno v:
Viruses, Vol 16, Iss 9, p 1465 (2024)
Background: Next-generation sequencing (NGS) kits are needed to finalise the transition from Sanger sequencing to NGS in HIV-1 genotypic drug resistance testing. Materials and Methods: We compared a homemade NGS amplicon-based protocol and the AD4SEQ
Externí odkaz:
https://doaj.org/article/b200756fe87d413595e552033bdd3b00
Autor:
Lia Fiaschi, Camilla Biba, Ilenia Varasi, Niccolò Bartolini, Chiara Paletti, Federica Giammarino, Francesco Saladini, Maurizio Zazzi, Ilaria Vicenti
Publikováno v:
Viruses, Vol 16, Iss 2, p 168 (2024)
Combination antiviral therapy may be helpful in the treatment of SARS-CoV-2 infection; however, no clinical trial data are available, and combined use of direct-acting antivirals (DAA) and monoclonal antibodies (mAb) has been reported only anecdotall
Externí odkaz:
https://doaj.org/article/1cc3c292e75a4be1a379cea3269fd9bd
Autor:
Ilaria Vicenti, Monica Basso, Nicole Pirola, Beatrice Bragato, Maria Cristina Rossi, Mario Giobbia, Susanna Pascoli, Antonio Vinci, Sara Caputo, Ilenia Varasi, Camilla Biba, Lia Fiaschi, Maurizio Zazzi, Saverio Giuseppe Parisi
Publikováno v:
Vaccines, Vol 11, Iss 4, p 871 (2023)
Live virus neutralization is the gold standard to investigate immunity. This prospective observational study aimed to determine the magnitude of response against the original B.1 lineage and against the BA.5 lineage six months after the third BNT162b
Externí odkaz:
https://doaj.org/article/9476e1dfc78e4ee186e75865c0066249
Autor:
Silvia Cesarini, Ilaria Vicenti, Federica Poggialini, Massimiliano Secchi, Federica Giammarino, Ilenia Varasi, Camilla Lodola, Maurizio Zazzi, Elena Dreassi, Giovanni Maga, Lorenzo Botta, Raffaele Saladino
Publikováno v:
Molecules, Vol 27, Iss 24, p 8829 (2022)
Current therapy against severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) are based on the use of Remdesivir 1, Molnupiravir 2, and the recently identified Nirmatrelvir 3. Unfortunately, these three drugs showed some limitations regar
Externí odkaz:
https://doaj.org/article/c0abea2af9b042f980b54cd2f982ba34